CSIMarket.com ’
In a significant move that aims to make transformative strides in biotechnology, Rafael Holdings, Inc. (NYSE: RFL) and Cyclo Therapeutics, Inc. (Nasdaq: CYTH) have announced a definitive merger agreement. This strategic alliance aims to synergize their efforts, capitalizing on Cyclo Therapeutics’ pioneering work on Trappsol Cyclo, a promising treatment for Niemann-Pick Disease Type C1 (NPC1). The merger is poised to strengthen both companies, potentially speeding up the timeline for bringing impactful therapeutics to market.
The Merger: Strategic Convergence for Therapeutic Advancement
The merger will see Rafael Holdings issue shares of its Class B common stock to Cyclo Therapeutics’ shareholders, based on an exchange ratio that values the Gainesville, Fla.-based company. This merger will help combine Rafael’s financial robustness and operational infrastructure with Cyclo Therapeutics’ innovative product pipeline and industry-leading research.
Niemann-Pick Disease Type C1 is an inherited, neurodegenerative disorder that affects various systems of the body, leading to symptoms such as difficulty in movement, liver and respiratory complications, and severe cognitive decline. Trappsol Cyclo, Cyclo Therapeutics’ leading drug candidate, has shown significant promise in treating the systemic and neurological manifestations of this rare disease.
The European Patent: A New Horizon in Alzheimer’s Disease Treatment
In addition to the merger, Cyclo Therapeutics celebrated another pivotal success with the European Patent Office’s decision to grant their patent application
Comments